CD274 and neoplasm: Increasing studies found that pre-treatment PD-L1 expression on tumor cells and immune cells was associated with improved response rate, progression-free survival (PFS) and overall survival (OS), and could effectively predict the clinical outcomes to ICB across various tumor types [7,8].